alcohol use disorder with depression - Nursing Case Study

Pathophysiology

• Primary mechanism: Chronic alcohol use leads to neurochemical imbalances, particularly affecting neurotransmitters like dopamine and serotonin. This reduces the brain's reward system sensitivity, contributing to both addiction and mood disturbances, as seen in depression.

• Secondary mechanism: Alcohol-induced neurotoxicity and inflammation can damage brain regions such as the prefrontal cortex and hippocampus, impairing emotional regulation and increasing vulnerability to depression.

• Key complication: This dual impact creates a vicious cycle where alcohol use exacerbates depressive symptoms, potentially leading to increased consumption as a maladaptive coping mechanism, complicating treatment and recovery efforts.

Patient Profile

Demographics:

42-year-old male, construction worker

History:

• Key past medical history: Alcohol use disorder diagnosed 5 years ago, major depressive disorder diagnosed 2 years ago, hypertension

• Current medications: Sertraline 50 mg daily, Lisinopril 10 mg daily

• Allergies: No known drug allergies

Current Presentation:

• Chief complaint: Increased alcohol consumption and worsening depressive symptoms over the past month

• Key symptoms: Daily alcohol intake exceeding 8 drinks, frequent mood swings, insomnia, fatigue, feelings of hopelessness, and occasional tremors

• Vital signs: Blood pressure 150/95 mmHg, heart rate 110 bpm, respiratory rate 18 breaths per minute, temperature 98.6°F

Section 1

Change in Patient Status:

During the follow-up visit, the patient presents with noticeable deterioration in his physical and psychological condition. His vital signs reveal a blood pressure of 160/100 mmHg and a heart rate of 120 bpm, indicating worsening hypertension and potential cardiovascular strain due to increased alcohol consumption. The patient reports persistent insomnia and has been experiencing more severe episodes of tremors, particularly in the mornings, which suggest early signs of alcohol withdrawal. His mood has further declined, with increased expressions of hopelessness and decreased motivation, impacting his ability to perform daily activities and maintain his work responsibilities.

Lab results show elevated liver enzymes, with AST and ALT levels at 85 IU/L and 90 IU/L respectively, suggesting hepatic stress or early liver damage due to chronic alcohol use. His serum magnesium level is low at 1.4 mg/dL, which could be contributing to his tremors and general fatigue. These findings highlight the need for immediate intervention strategies to address both his alcohol use disorder and the exacerbation of his depressive symptoms.

The healthcare team decides to initiate a more structured treatment plan, including a potential adjustment to his current medication regimen. The plan involves collaboration with a mental health professional to intensify counseling sessions and consideration of a detoxification program to manage alcohol withdrawal symptoms safely. The team also discusses the importance of a multidisciplinary approach involving a dietitian to address nutritional deficiencies and a physical therapist to help manage physical symptoms and improve overall well-being. This comprehensive strategy aims to stabilize the patient's condition, reduce alcohol intake, and improve his mental health, setting the stage for sustained recovery.

Section 2

Response to Interventions:

Two weeks after the implementation of the structured treatment plan, the patient returns for a follow-up appointment. There is a slight improvement in his physical and psychological condition, reflecting some initial positive responses to the interventions. His blood pressure has decreased to 150/95 mmHg and his heart rate to 110 bpm, indicating a modest reduction in cardiovascular strain. The patient reports that his insomnia has slightly improved with the introduction of cognitive behavioral therapy for insomnia (CBT-I) and a short course of non-benzodiazepine sleep aids. However, he continues to experience morning tremors, although they are less severe than before. This suggests a partial response to the magnesium supplementation and nutritional support provided by the dietitian.

The mental health counseling sessions have led to a slight improvement in his mood, with the patient expressing some hopefulness and increased willingness to engage in daily activities. However, he still struggles with maintaining motivation and focus at work. The detoxification program, initiated under medical supervision, has successfully reduced his alcohol intake, but complete abstinence remains a challenge. The patient acknowledges the ongoing support from his mental health counselor as crucial to managing his depressive symptoms while addressing his alcohol use disorder.

Despite these improvements, the healthcare team identifies the need for further adjustments. The patient's liver enzyme levels remain elevated, with AST at 80 IU/L and ALT at 85 IU/L, indicating that hepatic stress persists. To address this, the provider considers introducing pharmacological support such as naltrexone or acamprosate to aid in alcohol reduction and prevent relapse. Additionally, the team plans to increase the frequency of counseling sessions and explore the possibility of joining a support group to enhance the patient's social support network. These strategic modifications aim to sustain the positive trajectory and tackle ongoing challenges in his recovery journey.

Section 3

Two weeks after the last follow-up, the patient presents with new complications that require immediate attention. During this visit, he reports increased fatigue, abdominal discomfort, and a noticeable yellowing of the skin and eyes, suggesting the onset of jaundice. Upon examination, his vital signs reveal a blood pressure of 145/90 mmHg, a heart rate of 108 bpm, and slight tachypnea at 22 breaths per minute. These findings indicate a potential deterioration in his hepatic function, warranting further investigation. The healthcare team orders a comprehensive metabolic panel, revealing worsening liver enzyme levels with AST now at 120 IU/L and ALT at 130 IU/L, alongside elevated bilirubin levels at 3.2 mg/dL. These results confirm significant hepatic impairment, likely exacerbated by his ongoing struggle with alcohol use.

In response to these alarming findings, the team recognizes the urgency to modify the treatment plan. The introduction of naltrexone is reconsidered, given the contraindications with impaired liver function. Instead, the team opts to initiate acamprosate, which is less hepatotoxic, to support alcohol reduction and prevent relapse. Additionally, the patient is referred to a hepatologist for specialized care and further evaluation, including an abdominal ultrasound to assess for possible liver cirrhosis.

The increased frequency of mental health counseling sessions is emphasized, and the patient is strongly encouraged to join a support group. The healthcare team also discusses the possibility of a more intensive inpatient rehabilitation program, should his condition fail to improve with outpatient interventions. These adjustments aim to address both the psychological and physiological complications, emphasizing the critical need for ongoing monitoring and a comprehensive approach to his care. The unfolding scenario presents an opportunity for clinical reasoning as the team navigates the complexities of managing co-occurring alcohol use disorder and liver dysfunction.

Section 4

Two weeks following the initiation of acamprosate and intensified mental health counseling, the patient returns for a follow-up appointment. During the visit, he reports a slight decrease in alcohol consumption but admits to continuing episodes of binge drinking, particularly during periods of heightened stress. The patient also mentions persistent fatigue and intermittent confusion, which have begun to impact his ability to perform daily tasks. Physical examination reveals a further decline in his overall condition; his jaundice appears more pronounced, and he has developed mild ascites, suggesting worsening liver cirrhosis.

Vital signs taken during the visit show a blood pressure of 150/95 mmHg, a heart rate of 115 bpm, and a respiratory rate of 24 breaths per minute, indicating increasing cardiovascular strain likely related to his liver dysfunction. The healthcare team orders additional blood tests, revealing further elevation of liver enzymes, with AST climbing to 150 IU/L and ALT reaching 145 IU/L. His bilirubin levels have also increased to 4.0 mg/dL. These findings confirm continued hepatic deterioration, necessitating urgent adjustments to his management plan.

In response to the new complications, the team consults closely with the hepatologist, who recommends initiating diuretics to manage the ascites and adjusting the patient's diet to limit sodium intake. The possibility of hepatic encephalopathy is also considered, prompting the initiation of lactulose to reduce ammonia levels and address his confusion. Given the patient's limited progress with outpatient care, the healthcare team re-evaluates the need for inpatient rehabilitation, discussing the potential benefits with the patient and his family. This comprehensive approach underscores the complexity of managing dual diagnoses, highlighting the importance of interdisciplinary collaboration and ongoing reassessment of the patient's evolving clinical needs.

Section 5

As the healthcare team implements the revised management plan, the patient is admitted to the hospital for closer monitoring and more intensive treatment. Within the first 48 hours of admission, the patient's response to interventions is mixed. The administration of diuretics successfully reduces the ascites, evidenced by a measurable decrease in abdominal girth and reduced discomfort. However, the patient's cognitive status remains concerning. Despite the initiation of lactulose, episodes of confusion persist, suggesting the possibility of evolving hepatic encephalopathy. The medical team increases the frequency of lactulose dosing and emphasizes strict adherence to the medication regimen, while also ensuring the patient remains hydrated to prevent electrolyte imbalances.

Additional blood tests reveal worsening hyperammonemia, with ammonia levels rising to 85 mcg/dL, and further elevation of liver enzymes, with AST and ALT now at 160 IU/L and 155 IU/L, respectively. The patient's bilirubin level has increased to 5.2 mg/dL, indicating continued hepatic decline. Vital signs show persistent tachycardia at 120 bpm and hypertension at 155/100 mmHg, suggesting ongoing cardiovascular strain. These findings prompt renewed discussions with the hepatology team regarding the potential need for more aggressive interventions, such as consideration for liver transplant evaluation.

Despite these challenges, the patient exhibits some positive behavioral changes, expressing a greater willingness to engage with mental health support and acknowledging the severity of his condition. The healthcare team capitalizes on this motivation, reinforcing the importance of abstinence from alcohol and adherence to medical recommendations. Family members are also encouraged to participate in counseling sessions, aimed at strengthening the patient's support system and improving long-term outcomes. This phase of care highlights the importance of interdisciplinary coordination and patient-centered approaches in managing complex cases of alcohol use disorder with comorbid medical complications.